Introduction
Breast cancer is the most common cancer in women and ranks as second in the world in terms of cancer deaths. Recent studies using next generation sequencing (NGS) have shown that cancer evolves in the patient (1) (2) (3) , and therapies can induce the evolution of clones of cells that are refractory to the treatment (4, 5) . Much research has been devoted to developing bioassays that can help in the selection of therapies as (6) (7) (8) and prognosis (9). In contrast, circulating tumour DNA is detected in early and late stages in a high proportion of cases (10-12) and can persist for many years after supposedly successful therapy (13) despite no evidence of overt distant metastases. In metastatic breast cancer, the dynamics of circulating tumour DNA compare favourably to serum CA15-3 and CTC counts determined by CellSearch in reflecting changes in tumor burden (14) .
Metastases are heterogeneous, both between metastatic sites and also between the cells that compose each metastasis. Early metastases are comprised of a greater proportion of cells with EMT and 'stem-like' characteristics; whereas larger metastases are dominated by more differentiated, heterogeneous patterns of cells, more closely reflecting the heterogeneity seen in primary tumors (15) . Taking all these considerations into account, together with the well-established phenomenon of clonal evolution (16, 17) , it is evident that a single conventional tissue biopsy will not necessarily provide accurate information regarding appropriate therapy. An additional layer of complexity is suggested by the role of the immune system in patients with cancer, since immune destruction of persisting micrometastases could mean that the circulating tumour DNA is predominantly a reflection of destroyed cancer cells; whereas persisting CTCs could be envisaged as a more accurate guide to appropriate therapy.
Previous studies have compared mutations in cfDNA to either biopsies of metastases or CTCs (2, 18) . We reported emergence of ESR1 mutations in cfDNA and in a single patient with a very high CTC count (>3000 EpCAM-positive CTCs in 7.5ml blood) the ESR1 p.D538G mutation was detected in cfDNA and matched CTCs (2). Since cfDNA is in principal easier to obtain than CTCs for molecular analysis, it is essential to determine whether mutations in cfDNA are the same as those seen in individual CTCs, since heterogeneity is frequently observed in metastatic biopsies (19, 20) .
Here, we compared total cfDNA levels and CellSearch CTC counts with serum CA15-3 and alkaline phosphatase (ALP) levels in patients with metastatic breast cancer. We performed deep amplicon sequencing of 50 genes and compared mutation profiles in cfDNA and individual EpCAM-positive CTCs isolated from the same blood sample in 5 patients with high CTC counts (≥100 CTCs in 7.5ml blood).
Results show that cfDNA mutation profiles reflect mutational heterogeneity seen across individual CTCs; and that total cfDNA levels and ≥5 CTCs are significantly associated with overall survival. Circulating tumour DNA is a useful substitute for metastasis biopsy (18) . These data suggest that circulating tumour DNA reflects persisting EpCAM-positive CTCs in patients with high CTC counts and could enable monitoring of the metastatic burden, but requires confirmation in larger groups of patients.
Material and Methods
Research. 
Patients and samples
The study protocol was approved by the Riverside Research Ethics Committee (Imperial College Healthcare NHS Trust; REC reference number: 07/Q0401/20) and conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki. All patients gave written informed consent prior to participation. We recruited 112 patients with radiologically-confirmed metastatic breast cancer (Table   1 ). 20 ml of blood was taken into EDTA-tubes (BD Biosciences) and processed to plasma for cfDNA (21) and 7.5ml blood was taken into CellSave preservative tubes for CTCs capture and enumeration with the CELLSEARCH ® CTC Test (Janssen Diagnostics) as described previously (22) . CA15-3 and ALP results were obtained from patient notes.
Extraction and quantitation of DNA
CfDNA was isolated from 3 ml of plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to manufacturer's instructions. Isolation of DNA from lymphocytes and quantitation of total cfDNA was as described previously (21) .
cfDNA levels (ng/ml) were converted to copies/ml plasma assuming 3.3 pg DNA per haploid genome. FFPE tissue blocks with matching H&E were retrieved from the histopathology archive and reviewed by a consultant histopathologist. Two separate regions of tumour were then cored from the block using a 1 mm tissue microarray needle. DNA was extracted from the FFPE tissue core using the Qiagen GeneRead kit according to manufacturer's instructions. CTC isolation by DEPArray, QC to identify those samples with a genomic integrity index (GII) of 3 or 4 suitable for sequencing (20) and Ampli1 TM whole genome amplification were carried out as a service by
Research. Table 3 ). Three genes (PIK3CA, TP53 and ERBB2) were on both panels making a total of 50 genes surveyed for hotspot mutations. Overlapping mutations were reviewed in IGV if they were only detected on one panel. In total the two panels surveyed ~2200 COSMIC ID mutations.
Sequencing on a 316 chip using the Ion PGM and data analysis was as described previously (2) . In brief, sequencing data was accessed through the Torrent Suite v.4.2.0. Reads were aligned against the human genome (hg19) using Alignment v4.0-r77189 and variants called using the coverageAnalysis v4.0-r77897 and variantCaller v4.0-r76860, respectively. Due to the sensitivity of the in house panel, for cfDNA and FFPE tumour tissue variantCaller was configured to call on high stringency, somatic variants with down sampling set to 6000 and gen_min_coverage set to 6. COSMIC IDs were obtained using COSMIC v71
Research. February 2016). Variants in individual CTCs and WBCs were analysed using a preset high stringency germline threshold, as recommended by the manufacturer, which is optimised for high-frequency variants and minimal false positive calls. The allelic dropout rate (ADR) and false positive rate (FDR) was calculated as described by Leung et al. (23) . All mutations with a quality score below 25 were omitted and all variants detected in the first or last 10 bases of an amplicon were omitted as likely mispriming events (2, 24) . ANNOVAR (25) was used to annotate all private mutations with refGene ID, functional consequence (e.g., non-synonymous), and functional predictions (using SIFT (26), Polyphen-2 (27) , and MutationTaster (28)).
All variants detected were also manually confirmed across all samples using the 
Digital droplet PCR (ddPCR)
Droplet digital PCR was used to validate selected mutations in ESR1 p.Y537C/N/S, p.D538G; PIK3CA p.E545K and H1047R, and KRAS p.G12D. Each assay was performed in duplicate using a Bio-Rad QX200 digital droplet PCR system as described previously (31) . Inventoried assays were used for detection of PIK3CA p.E545K (assay numbers dHsaCP2000075 and dHsa2000076) and p.H1047R (assay numbers dHsaCP2000077 and dHsaCP2000078) and KRAS p.G12D (assay numbers strategy was used (see Supplementary Table 4 for sequences). Thermal cycling conditions for the ESR1 assays were: 10 min hold at 95 °C, 40 cycles of 95 °C for 15 s then 60 °C for 60 s. Raw fluorescence amplitude was analysed using the Quantasoft version 1.6.6.0320 software and used to obtain the fractional abundance for a given mutation. This was reported as the allele frequency (AF) to be consistent with NGS data. Calculation of the allele fraction (AF) was performed as described previously (32, 33). The total number of droplets (with and without DNA) was used to calculate DNA copies/μl, then dividing the number of mutant copies by the number of total DNA copies (mutant plus wild-type) and multiplying by 100 to give the percentage (allele fraction) of mutant DNA copies based on Poisson distribution of positive to empty droplets (33).
Statistical analysis
Correlation analysis of total cfDNA levels, CA15-3, ALP and CTC counts was performed using a non-parametric Spearman's correlation. P values were two-tailed and considered significant if P < 0.05. Survival analysis was performed using multiple Cox-regression as described previously (14) with each biomarker as a continuous time-dependent variable (Supplementary Table 5 ). Briefly, for each variable a model was constructed using a counting process notation (i.e. start, end, event). In our study, start was taken as the date of the baseline blood sample, and the end was taken as an arbitrary cut-off of 01/12/2015.
Results
This was a prospective study set up to identify patients with high CTC counts (≥100 CTCs per 7. threshold of ≥100 CTCs per 7.5 ml blood was based on a previous study by Polzer et al. (20) , that analysed individual CTCs from patients with similar high CTC counts but did not compare individual CTCs with matched cfDNA. We recruited 112 patients with metastatic breast cancer to the study (Table 1) . Each had undergone multiple lines of treatment. Sixty-one patients were CTC negative and 51 patients had ≥1
CTCs measured by CellSearch (median, 5; range 1 -701). Serum CA15-3 levels were elevated (>30 U/ml (34)) in 72 patients (64%), ALP was elevated (>100 IU/L) in 40 patients (36%) and both were elevated in 31 (28%). Total cfDNA was obtained for all samples (median, 2757 copies/ml of plasma; range 30 copies -115724 copies/ml of plasma). The markers were significantly correlated (Spearman's correlation analysis; Supplementary Table 6), except cfDNA and CA15-3 (P = 0.058). High CTC count (≥5 CTCs) (HR, 2.8, 95% CI, 1.4 to 5.7; P = 0.005) and total cfDNA level (hazard ratio (HR), 2.2; 95% CI, 1.3 to 3.6; P = 0.03) were significantly associated with poorer overall survival (Supplementary Table 6 ).
cfDNA and individual CTCs have overlapping mutation profiles
At the time of the study we had established that adequate cells could be obtained from the DEPArray system for patients with high CTC counts (≥100 CTCs per 7.5ml blood) based on a previous study (20) . We therefore chose five patients with high Table 7 ). The allelic dropout rate (ADR) across individual CTCs and WBCs, and the false positive rate (FPR) for SNVs were 25.01%; SEM 2.68% , and 0.6%; SEM 0.32% respectively (Supplementary Table 8 ), within the range reported previously (23) . Mutations were only called in individual CTCs and WBCs if these were present in 2 or more single cells (23) . Overall only 3 individual CTCs had no coverage at a specific mutated base (Table 2) . In each case, the mutation was called in other CTCs and the matched plasma cfDNA.
Although we examined mutation hotspots in 50 genes across 2 amplicon panels by NGS, mutations were only detected by NGS in 4 genes in ESR1, PIK3CA, TP53 and KRAS. Two of these PIK3CA, TP53 were common to both panels. Droplet digital PCR was used as validation for ESR1 p.Y537C/N/S, p.D538G; PIK3CA p.E545K and H1047R, and KRAS p.G12D when sufficient remaining DNA was available.
Research.
on
Overall, 4 patients had mutations detected in PIK3CA, TP53, ESR1 and KRAS genes in cfDNA and individual EpCAM-positive CTCs ( Fig. 2; Table 2 ). Levels of circulating tumour DNA varied. The mean plasma mutant allele frequency (AF) ranged from 0.3% to 32% and a rise in levels of circulating tumour DNA generally accompanied a rise in total cfDNA (Fig. 2) . Mutational heterogeneity was seen between individual EpCAM-positive CTCs isolated from the same blood sample with the majority of CTCs having 1, 2 or no mutations detected. All mutations detected in individual EpCAM-positive CTCs were detected in the matched cfDNA (Table 2 ).
PIK3CA and TP53 gene mutations were also present in the primary tumour DNA; whereas ESR1 and KRAS mutations were unique to cfDNA and EpCAM-positive individual CTCs (Table 2) suggesting potential clonal evolution. Private mutations of unknown significance were also detected in individual CTCs and WBCs (Supplementary Table 9 ); however these were excluded as likely amplification artefacts as they were not detected in the matched CTC pool, WBC pool or primary tumour (Supplementary Tables 10-13 ).
Patient CTCM155 (ER positive, HER2 negative) had two blood samples taken 11 months apart (Supplementary Fig. 1 ). Plasma cfDNA was only available for the first sample, as insufficent blood was obtained at the second time point for both cfDNA and CTCs. EpCAM-positive CTCs were detected in the second sample after progressing on exemestane and everolimus combination therapy. The primary tumour and baseline cfDNA had a PIK3CA mutation (p.H1047R, AF 70% and 23%, respectively). A second lower frequency ESR1 mutation (p.E380Q, AF 3.9%) was also detected in cfDNA suggesting either a subclonal origin or that this mutation was
acquired on treatment. All 5 individual CTCs and the CTC pool had both mutations (Table 2, Supplementary Table 10) .
Patients with rising circulating tumour DNA
Patient CTCM138 (ER positive, HER2 negative) had a PIK3CA (p.H1047R) mutation (AF 25%) and low frequency sub-clonal TP53 (p.R175H) mutation (AF 1.5%) in primary tumour DNA. She was recruited to the study in 2014 some 10 years after diagnosis of breast cancer and having received multiple lines of endocrine therapy.
Both mutations seen in the primary tumour were detected in baseline cfDNA (PIK3CA AF 32%, TP53 AF 3.7%) as well as an acquired ESR1 (p.E380Q) mutation (AF 24.2%). The second blood sample was taken 7 months later just prior to clinical disease progression. Levels of circulating tumour DNA increased from baseline, the 3 mutations persisted and a second ESR1 mutation (p.Y537C) was acquired at a low level (AF 0.43%) ( Fig. 2a and d; Supplementary Table 11 ). Five individual CTCs were isolated from the second blood sample, 2 of which had the PIK3CA (p.H1047R) and ESR1 (p.E380Q) mutations, but not the lower frequency ESR1 p.Y537C or TP53 p.R175H mutations (Table 2) , although these could have been missed by sampling 5 individual CTCs.
Patient CTCM105 (Triple negative) was recruited to the study in March 2014 with progressive disease. No mutations were detected across the 50 genes in either the primary tumour or baseline cfDNA sample. A second blood sample was taken 11 months later. Six of 9 individual CTCs isolated from this sample had a KRAS (p.G12D) mutation that was also detected in the CTC pool ( Fig. 2b, d 3.8%) (Fig. 2d) and a low-frequency mutation in TP53 (p.P278R) (AF 2.3%). The low frequency TP53 mutation might be missed by sampling 9 CTCs; however, it is also possible that 2 metastatic clones were shedding DNA in to plasma, one reflected in CTCs, one not. As neither mutation was detected in the FFPE primary tumour tissue these may either have been acquired on treatment or have arisen from a minor subclone missed by tumour sampling.
Patient CTCM292 (ER positive, HER2 negative) presented with bone metastases in 2012 and was treated with tamoxifen. She subsequently relapsed and commenced letrozole, which was then switched to chemotherapy with paclitaxel, then epirubicin.
Three serial blood samples were taken over a 12 month period commencing upon letrozole. No mutations were detected in the baseline cfDNA sample, but 2 mutations were detected 6 months later, while she was on letrozole (ESR1 p.D538G AF 28% and PIK3CA p.E545K 19.7%) and then reduced at 12 months on paclitaxel (AF 0.27% and 0.17%, respectively) (Fig. 2c) . Both mutations were also present in individual EpCAM-positive CTCs isolated from the third blood sample (Fig. 2c , Table 2; Supplementary Table 13) .
Lastly, the fifth patient (CTCM167: ER positive, HER2 negative) was monitored over an 18 month period and had a marked rise in total cfDNA levels and CTC counts at disease progression ( Supplementary Fig. 2 ). No mutations were identified in the 50 genes analysed in FFPE primary tumour DNA. Moreover, there was no evidence for acquisition of mutations across the 50 genes in either cfDNA or individual CTCs from two serial blood samples (Table 2) . 
Discussion
CTCs are an established prognostic indicator in metastatic breast cancer (7, 9, 35) . A recent study has shown that it is possible to interrogate both cfDNA and pools of mutation-bearing CTCs from the blood of patients with metastatic breast cancer (36).
Here, we present results of mutations in multiple individual CTCs and matched cfDNA in patients with metastatic breast cancer and high CTC counts. First, in 4 patients we observed heterogeneity in mutations between individual EpCAM-positive CTCs. In all 4 patients cfDNA profiles provided an accurate reflection of mutations see in individual CTCs, and in 2 patients cfDNA had more mutations than those found in CTCs. ESR1 and KRAS gene mutations were present in individual CTCs and cfDNA but were absent from primary tumour tissue. Therefore, these likely reflect either a minor sub-clonal mutation or were acquired with disease progression. Of note, the primary tumour, serial cfDNA samples and multiple individual CTCs from 1 of the 5 patients (CTCM167) had no hotspot mutations detected across the 50 genes.
Further analysis, such as whole exome sequencing or array CGH is needed to identify mutations and copy number variation in these samples.
Second, in 2 patients, mutations were detected in cfDNA (in TP53 (p.P278R) and in TP53 (p.R175H) and ESR1 (p.Y537C)) that were not seen in individual CTCs or the CTC pool isolated from the same blood sample. As these were low frequency (and likely sub-clonal) mutations these may have been missed by sampling small numbers of individual CTCs. It is also possible that these were missed due to allelic distortion/dropout, which had an average frequency of 25.46% across the samples analysed, similar to a previous single cell genomics study (23) . Of note, in a previous study (2), we also identified an ESR1 gene mutation unique to cfDNA that was not Although we sequenced ~2200 COSMIC mutations across 50 genes in 5 patients, mutations were only detected in 4 genes (PIK3CA, ESR1, TP53, and KRAS ) and only 1 or 2 mutations were detected in the majority of samples. This is consistent with a recent study, which used the same platform and a 50 gene panel (41) . TP53 and PIK3CA are the most frequently mutated genes in breast cancer; however, a large number of other genes are less commonly mutated (42) . Whole exome or whole genome analysis of the primary tumour/metastatic tissue would be required to determine additional mutations not covered by the targeted sequencing approach.
However, metastatic tissue is frequently impossible to obtain in this group of patients.
ESR1 mutations have been linked to increased invasive and metastatic behaviour (43).
The ESR1 p.D538G mutation leads to ligand-independent activation of ERα, and is acquired in patients who have received aromatase inhibitors. The p.E380Q mutation 
has also been reported; but according to Li et al. (44) , remains sensitive to antioestrogens. In one patient we saw evidence of mutational heterogeneity in ESR1, with p.E380Q at a higher level than p.Y537C in cfDNA, suggesting heterogeneous clonal responses to treatment, as reported in a recent study (45) . The PIK3CA p.E545K mutation affects the helical region of the P110alpha catalytic domain (46); whereas the p.H1047R mutation affects the kinase domain, and induces a multi-potent genetic programme in normally lineage-restricted populations at an early stage of tumor development leading to intra-tumoral heterogeneity (47) . high CTC counts show that cfDNA sequencing finds more mutations than CTCs as well as mutations not seen in the primary tumour. Our CTC data highlights the mutational heterogeneity of single EpCAM-positive CTCs, supporting other recent studies (19, 20) . In 2 out of the 4 patients with mutations detected in CTCs mutations were only detected in about half of the CTCs sequenced (Table. 2). Together these results suggest that if EpCAM-positive CTCs were to be used, concurrent analysis of multiple CTCs may be necessary for clinical decision-making, particularly when metastatic biopsy is not possible. In aggregate our results suggest that cfDNA reflects persisting EpCAM-positive CTCs in patients with high CTC counts and could enable monitoring of the metastatic burden for clinical decision-making. Lastly, our results also suggest that total cfDNA levels are also an independent indicator of overall survival (P = 0.03), but a confirmatory study is needed in a larger series of patients.
Further studies are ongoing to examine the relationship between CTCs and cfDNA using Parsortix filtration (55), an alternative marker independent approach for CTC isolation. 
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